August 23, 2017 2:56 AM ET


Company Overview of Cephalon, Inc.

Company Overview

Cephalon, Inc. engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. It offers NUVIGIL (armodafinil) tablets for improving wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea and shift work disorder, also known as shift work disorder and narcolepsy; TREANDA (bendamustine HCl) for injection for the treatment of patients with chronic lymphocytic leukemia; and AMRIX (Cyclobenzaprine Hydrochloride extended-release capsules), which is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute and painful musculoskeletal conditions. The company also provi...

41 Moores Road

Frazer, PA 19355

United States

Founded in 1987

3,726 Employees





Key Executives for Cephalon, Inc.

Chief Financial Officer, Principal Accounting Officer and Executive Vice President
Age: 59
Executive Vice President and President of Cephalon Europe Operations
Age: 65
Executive Vice President, Secretary and General Counsel
Age: 53
Chief Medical Officer and Executive Vice President
Age: 56
Chief Scientific Officer and Executive Vice President
Age: 66
Compensation as of Fiscal Year 2017.

Cephalon, Inc. Key Developments

Wockhardt Limited, Wockhardt UK Holding Limited and CP Pharamaceuticals Limited Settle Commercial Litigation in the High Court, London with Teva Pharmaceuticals USA, Inc. and Cephalon Inc

Wockhardt Limited announced that, WL and two subsidiaries, Wockhardt UK Holding Limited and CP Pharamaceuticals Limited, in the United Kingdom have settled an ongoing commercial litigation before the High Court in London, United Kingdom in relation to supply contract for a drug named Trisenox. The dispute between the parties was in respect of the price charged by CP to its counterparty to the contract, Cephalon Inc, (Cephalon) an affiliate of Teva Pharmaceuticals USA, Inc. (Teva). The proceedings commenced in September 2015. Under the referred settlement between the parties, CP has agreed to waive its claim for the outstanding trade receivable of GBP 20 million and accordingly dropped its counterclaim for the said amount and further paid a sum of GBP 23 million to Teva and Cephalon by way of full and final settlement of Teva’s claims. The High Court has accepted the settlement between the parties and a Consent Order was issued on June 21, 2017.

Cephalon, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., and Barr Pharmaceuticals, Inc. Announce Settlement for Purchasers of Provigil® or Generic Versions of Provigil® (Modafinil)

A proposed settlement has been reached in a lawsuit regarding the price that individuals in 48 states and the District of Columbia paid for Provigil® and generic versions of Provigil®.  The lawsuit asserts that defendants Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., and Barr Pharmaceuticals, Inc., (all collectively, "defendants") violated antitrust laws relating to the sale of the prescription pharmaceutical Provigil®. All defendants have denied any wrongdoing. Provigil (modafinil) is used to treat excessive sleepiness caused by sleep apnea, narcolepsy, or shift work sleep disorder. If customers have purchased Provigil® and/or modafinil between June 24, 2006 and March 31, 2012, may be entitled to a payment from the settlement fund. The defendants will pay a total of $35 million into a settlement fund to settle all claims in the lawsuit brought on behalf of consumers. The Settlement Fund will be distributed pro rata to consumers who file a valid Claim Form.

A.G. Schneiderman Announces $125 Million Settlement with Cephalon that Impeded Competition by Generic Prescription Makers

Attorney General, Eric T. Schneiderman has announced a $125 million, 48-state settlement with drug manufacturer Cephalon and affiliated companies (Cephalon), now part of Teva Pharmaceutical Industries. The settlement ends a multistate investigation into anticompetitive conduct by Cephalon to protect the profits it earned from having a patent-protected monopoly on the sale of its landmark drug, Provigil. Cephalon's conduct delayed generic versions of Provigil from entering the market for several years. As patent and regulatory barriers that prevented generic competition to Provigil neared expiration, an investigation found that Cephalon intentionally defrauded the Patent and Trademark Office to secure an additional patent, which a court subsequently deemed invalid and unenforceable. Before that court finding, Cephalon was able to delay generic competition for nearly six additional years by filing patent infringement lawsuits. Cephalon settled those lawsuits by paying competitors to delay sale of their generic versions of Provigil until at least April 2012. Because of that delayed entry, consumers, states, and others paid hundreds of millions more for Provigil than they would have had generic versions of the drug launched by early 2006, as expected. The settlement includes $35 million for distribution to consumers who bought Provigil. New York's total recovery will be $6 million in compensation to certain state entities and others who bought off of state contracts; an estimated $3.1 to $4.8 million for distribution to New York consumers who purchased Provigil; and $1.3 million for disgorgement and costs. This multistate settlement was facilitated by Federal Trade Commission litigation against Cephalon. In May 2015, the FTC settled its suit against Cephalon for injunctive relief and $1.2 billion, which was paid into an escrow account. The FTC settlement allowed for those escrow funds to be distributed for settlement of certain related cases and government investigations. The settlement is subject to court review, including providing consumers with notice and an opportunity to participate in, object to, or opt out of settlement. The states expect court review will be provided by Judge Mitchell Goldberg of the Eastern District of Pennsylvania, who is overseeing other litigation concerning Provigil against Cephalon and others.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Cephalon, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at